Immunic (IMUX) Enterprise Value (2013 - 2026)

Immunic has disclosed Enterprise Value across 14 years of filings, most recently posting -$186.6 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$186.6 million, down 1204.73% year-over-year; the trailing twelve-month figure through Mar 2026 was -$186.6 million (down 1204.73% YoY), and the FY2025 annual result was -$15.5 million, up 56.59% from the prior year.
• Enterprise Value came in at -$186.6 million for Q1 2026 at Immunic, down from -$15.5 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$14.3 million in Q1 2025 to a low of -$186.6 million in Q1 2026.
• The 5-year median for Enterprise Value is -$72.8 million (2022), against an average of -$72.5 million.
• Across the five-year window, Enterprise Value surged 85.3% in 2025 and slumped 1204.73% in 2026, its largest moves.
• Immunic's Enterprise Value stood at -$116.4 million in 2022, then surged by 59.89% to -$46.7 million in 2023, then increased by 23.58% to -$35.7 million in 2024, then jumped by 56.59% to -$15.5 million in 2025, then sank by 1105.38% to -$186.6 million in 2026.
• The last three Enterprise Value figures came in at -$186.6 million (Q1 2026), -$15.5 million (Q4 2025), and -$35.1 million (Q3 2025), per Business Quant data.